Abstract : The aim of the study was to elucidate a plausible predictive value of the macrophage migration inhibitory factor (MIF) levels for one-year clinical outcomes in ST-segment elevation myocardial infarction (STEMI) patients underwent primary percutaneous coronary intervention (PCI). Materials and methods: 134 STEMI patients underwent PCI were enrolled in the study. The MIF levels were determined at baseline, directly prior and after PCI along with conventional observations. Results. During 1-year follow-up 37% of patients has reached the composite endpoint (all-cause mortality, non-fatal STEMI, and non-fatal stroke, hospitalization for unstable angina, heart failure decompensation, and PCI). We have found that pre-PCI MIF levels > 3934 pg/mL might be an independent predictor of composite endpoints with sensitivity 54% and specificity 82%. Positive correlation between MIF and inflammatory biomarkers was revealed. Adverse outcomes associated with higher pre- and post-PCI MIF levels (OR 1.0, 95% CI 1.0001–1.0008; p=0.013 and OR 1.0, 95% CI 1.0001–1.0009; p=0.019) and CRP that determined during the first week after the event (OR 1.0, 95% CI 1.005–1.2, p=0.03). Kaplan-Meier analysis has shown substantially lower long-term survival rate in patients with the MIF level > 3493 pg/ml when compared with the MIF level ≤ 3493 pg/ml. Conclusions: The MIF levels exceeded 3934 ng/ml were associated with the higher risk of one-year adverse clinical outcome in STEMI patients underwent primary PCI

Volume and Issue
Full Article Download